Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma (TRITICC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04059562
Recruitment Status : Not yet recruiting
First Posted : August 16, 2019
Last Update Posted : November 13, 2019
Sponsor:
Collaborator:
Servier
Information provided by (Responsible Party):
RWTH Aachen University

Brief Summary:

This is a prospective, single arm, open label, non-randomized, exploratory, multi-centre pilot study with median progression free survival as primary outcome.

In total 28 patients (including 3 calculated drop outs and invalid cases) with advanced cholangiocellular carcinoma after failure of a gemcitabine based first-line therapy will be enrolled at 5 centres.

To examine the efficacy of a combination therapy of Trifluridine/Tipiracil and Irinotecan in patients with advanced, non resectable or metastatic cholangio- and gallbladder carcinoma after failure to respond to a previous gemcitabine treatment.

The study will be accompanied by a translational research program:

Before treatment and after each radiological tumor assessment (Q6W) blood and stool will be collected and extensive panels of biomarkers will be accessed.


Condition or disease Intervention/treatment Phase
Cholangiocarcinoma Combination Product: Combination of Lonsurf® and Campto® Phase 2

Detailed Description:

This is a prospective, single arm, open label, non-randomized, exploratory, multi-centre pilot study with median progression free survival as primary outcome.

In total 28 patients (including 3 calculated drop outs and invalid cases) with advanced cholangiocellular carcinoma after failure of a gemcitabine based first-line therapy will be enrolled at 5 centres.

To examine the efficacy of a combination therapy of Trifluridine/Tipiracil and Irinotecan in patients with advanced, non resectable or metastatic cholangio- and gallbladder carcinoma after failure to respond to a previous gemcitabine treatment.

The study will be accompanied by a translational research program:

Before treatment and after each radiological tumor assessment (Q6W) blood and stool will be collected and extensive panels of biomarkers will be accessed.

Patients will be treated until radiological progression. In average this will be about 4 months. A follow up is planned every 3 months up to 6 months to asses life quality and progression data.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Combination of Lonsurf® and Campto® in 28 patients with cholangiocarcinoma.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma
Estimated Study Start Date : January 1, 2020
Estimated Primary Completion Date : February 1, 2022
Estimated Study Completion Date : August 1, 2022


Arm Intervention/treatment
Experimental: Treatment
Combination of Lonsurf® and Campto®
Combination Product: Combination of Lonsurf® and Campto®

Trifluridine/Tipiracil (Lonsurf®) and Irinotecan (Campto®)

  • Trifluridine/Tipiracil will be administered at a dose of 25 mg/m2 / dose twice daily on days 1-5 followed by a 9-days recovery period from day 6 trough day 14 of each 14-days treatment cycle.
  • Irinotecan will be administered at the same time as Trifluridine/Tipiracil (Lonsurf®) on day 1 of each cycle at a dose of 180 mg/m2 / dose.




Primary Outcome Measures :
  1. Median progression free survival (PFS) [ Time Frame: through study completion, an average of 1 year (~4 months intervention + 6 months Follow Up) ]
    Median progression free survival (PFS)


Secondary Outcome Measures :
  1. Progression-free survival rate [ Time Frame: At 4 months ]
    Progression-free survival rate @ 4 months defined as the proportion of patients with non-progressive disease 4 months after inclusion by intention to treat analysis

  2. Median overall survival [ Time Frame: through study completion, an average of 1 year (~4 months intervention + 6 months Follow Up) ]
    Median overall survival

  3. Response according to RECIST 1.1 [ Time Frame: through study completion, an average of 1 year (~4 months intervention + 6 months Follow Up) ]
    Proportion of patients with an objective response according to RECIST 1.1

  4. Safety (type, grade and frequency of Adverse Events (AEs)/Serious Adverse Events (SAEs)) [ Time Frame: through study completion, an average of 1 year (~4 months intervention + 6 months Follow Up) ]
    Safety (type, grade and frequency of AEs/SAEs)

  5. Quality of life - European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-30) [ Time Frame: through study completion, an average of 1 year (~4 months intervention + 6 months Follow Up) ]
    Analysis of quality of life (EORTC QLQ-30)

  6. Quality of life - EuroQol-5Dimensions-3Levels (EQ-5D-5L) questionnaires [ Time Frame: through study completion, an average of 1 year (~4 months intervention + 6 months Follow Up) ]
    Analysis of quality of life (EQ-5D-5L questionnaires)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed consent incl. participation in translational research and any locally-required authorization (EU Data Privacy Directive in the EU) prior to performing any protocol-related procedures, including screening evaluations
  2. Age ≥ 18 years at time of study entry
  3. Histologically or cytologically confirmed, non-resectable, locally advanced or metastatic cholangiocarcinoma or gall bladder carcinoma
  4. Measurable or assessable disease according to RECIST 1.1
  5. Documented disease progression after prior gemcitabine or gemcitabine containing therapy. Examples of permitted therapies include, but are not limited to: a) Single agent gemcitabine); b) Any gemcitabine-based regimen, with or without maintenance gemcitabine
  6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  7. Ability to take medications orally
  8. Adequate blood count, liver-enzymes, and renal function:

    • Absolute neutrophil count (ANC) > 1,500 cells/μL without the use of hematopoietic growth factors; and Platelet count ≥ 100 x 109/L (>100,000 per mm3) and Hemoglobin > 9 g/dL (blood transfusions are permitted for patients with hemoglobin levels below 9 g/dL)
    • Serum total bilirubin ≤ 1.5x upper normal limit (ULN) (biliary drainage is allowed for biliary obstruction; elevated bilirubin should be caused by obstruction not impaired liver function as assessed by albumin and international normalised ratio (INR) values):
    • Albumin levels ≥ 3.0 g/dL
    • Patients not receiving therapeutic anticoagulation must have an INR< 1.5 ULN and partial thromboplastin time (PTT) < 1.5 ULN within 7 days prior to inclusion. The use of full dose anticoagulants is allowed as long as the INR or PTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least three weeks at the time of inclusion.
    • aspartate aminotransferase (AST) (SGOT) and Alanine transaminase (ALT) (SGPT) ≤ 5 x institutional upper limit of normal
    • Serum Creatinine ≤ 1.5 x ULN and a calculated glomerular filtration rate ≥ 30 mL per minute Adequate renal and bone marrow function
  9. In case of liver cirrhosis: Child-Pugh A
  10. Women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control

Exclusion Criteria:

  1. Age < 18 years
  2. Central nerve system (CNS) metastases
  3. Active, uncontrolled infection
  4. Additional malignancy within the past 2 years (except adequately treated in-situ carcinoma of the cervix or non-melanoma skin cancer)
  5. Clinically significant gastrointestinal disorders including bleeding, inflammation, occlusion, or diarrhea > grade 1
  6. Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
  7. Known hypersensitivity to Trifluridine/Tipiracil or Camptothecin (CPT)-11 or their components
  8. Medication that is known to interfere with any of the agents applied in the trial
  9. Pregnancy or lactating female
  10. Prior partial or total gastrectomy
  11. Previous radio- or radiochemotherapy, previous transarterial chemoembolisation (TACE), radiofrequency ablation (RFA) or selective intraarterial radiotherapy (SIRT) within 3 months prior to inclusion (except radiation for bone metastases)
  12. Patients who might be dependent on the sponsor, site or the investigator
  13. Patients who have been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.
  14. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a German drug law (AMG)].

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04059562


Contacts
Layout table for location contacts
Contact: Christina Kalvelage, M.Sc. 0241 80 36485 ckalvelage@ukaachen.de
Contact: Maike Kortmann, M.Sc. 0241 80 37910 mkortmann@ukaachen.de

Sponsors and Collaborators
RWTH Aachen University
Servier
Investigators
Layout table for investigator information
Principal Investigator: Christoph Roderburg, PD Dr. med. Klinik für Gastroenterologie, Stoffwechselerkrankungen und Internistische Intensivmedizin (Med. Klinik III), Uniklinik RWTH Aachen

Publications:

Layout table for additonal information
Responsible Party: RWTH Aachen University
ClinicalTrials.gov Identifier: NCT04059562    
Other Study ID Numbers: 17-157
First Posted: August 16, 2019    Key Record Dates
Last Update Posted: November 13, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Cholangiocarcinoma
Adenocarcinoma
Carcinoma
Trifluridine
Irinotecan
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antimetabolites
Antiviral Agents
Anti-Infective Agents